Stacy Blum
Family Medicine · Nebraska City, NENPI 1174530976
Payments from drug & device makers
Across 432 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$918
- Amgen$832
- Lilly USA, LLC$442
- Pfizer$415
- Astellas Pharma US Inc$365
- plus $2K from 38 others
What the payments were for
- Food & beverage$6,82598%
- Education$1202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,945 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 168 | $145,297 |
| MounjaroTirzepatide | 75 | $88,899 |
| FarxigaDapagliflozin Propanediol | 100 | $82,783 |
| JardianceEmpagliflozin | 74 | $70,672 |
| OzempicSemaglutide | 53 | $59,442 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $50,077 |
| XareltoRivaroxaban | 58 | $42,683 |
| RybelsusSemaglutide | 25 | $35,874 |
| TrulicityDulaglutide | 35 | $34,635 |
| MyrbetriqMirabegron | 43 | $32,849 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $16,391 |
| Repatha SureclickEvolocumab | 27 | $15,673 |
| LinzessLinaclotide | 19 | $15,366 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 49 | $14,175 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $12,768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $415 | $150,328179 claims |
| Lilly USA, LLCMounjaro, Trulicity | $442 | $123,534110 claims |
| Novo NordiskOzempic, Rybelsus | $334 | $95,31678 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix, Anoro Ellipta | $38 | $90,690195 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $918 | $87,289111 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $183 | $87,06396 claims |
| Johnson & JohnsonXarelto, Invokana | $132 | $55,27479 claims |
| Astellas Pharma US IncMyrbetriq | $365 | $32,84943 claims |
| AbbVieLinzess, Synthroid | $1,481 | $18,36067 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Nebraska City
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.